This is Thomas Sullivan - Policy & Medicine Writing Staff's Typepad Profile.
Join Typepad and start following Thomas Sullivan - Policy & Medicine Writing Staff's activity
Join Now!
Already a member? Sign In
Thomas Sullivan - Policy & Medicine Writing Staff
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
Many in political (and non-political) circles have blamed a lack of pricing transparency for increasing healthcare costs. However, as recognized in a study published in The Journal of the American Medical Association, improving transparency is not the answer. More than... Continue reading
Posted 16 hours ago at Policy and Medicine
Image
In a last-minute attempt to put a permanent mark on the life sciences (and specifically, the medical device) industry, the outgoing Obama Administration issued a litany of final and draft guidances in a roughly six-week period. This article briefly reviews... Continue reading
Posted 16 hours ago at Policy and Medicine
Image
As many of our readers know all too well, pharmaceutical companies are not permitted to discuss off-label, legal, alternative uses for an approved drug with physicians and other healthcare professionals as regulated by the FDA. However, a bill in Arizona,... Continue reading
Posted yesterday at Policy and Medicine
Image
Last Friday, several of our readers emailed us last week to let us know that they were having difficulty with logging in and processing files in the CMS Open Payments Portal in preparation for the March 31st submission deadline. On... Continue reading
Posted yesterday at Policy and Medicine
Image
We have written for years about the transition in health care from volume-based to value-based payment models. But the process has been a slow one. According to the Deloitte 2016 Survey of US Physicians, a nationally representative sample of 600... Continue reading
Posted 4 days ago at Policy and Medicine
Image
The 4th Due Diligence Summit for Life Sciences, taking place on May 18 and 19 of this year in Boston, Massachusetts at the Hyatt Regency Boston. This is a cross-functional life science event focused on the needs of due diligence... Continue reading
Posted 4 days ago at Policy and Medicine
Image
Part of President Obama’s landmark health care bill, the Affordable Care Act, imposed a federal tax on medical devices. That tax was temporarily suspended in January 2016, which allowed some medical device companies (i.e., OrthoPediatrics Corp. based in Northern Indiana)... Continue reading
Posted 5 days ago at Policy and Medicine
Image
In late-February, we reported that CMS had recently finalized new Innovation Center models. However, now, in an interim rule, CMS is delaying the implementation of the mandatory cardiac bundle program and cardiac rehabilitation program from July 1 to Oct. 1.... Continue reading
Posted 6 days ago at Policy and Medicine
Image
Recently, as part of the course Legal Compliance Essentials for Drug, Device and Biotech Companies, Mitchell Hamline Law School, students were asked to write about what they saw as the important emerging issues for life sciences and what compliance professionals... Continue reading
Posted 6 days ago at Policy and Medicine
Image
The United States Food and Drug Administration (FDA) offers a podcast series, known as the Director’s Corner, that features the director of the FDA Center for Drug Evaluation and Research (CDER). One of the most recent episodes featured an interview... Continue reading
Posted 7 days ago at Policy and Medicine
Image
National health expenditure is expected to grow an average of 5.6% annually from 2016 through 2025, according to a report published by Health Affairs (authored by the Centers for Medicare & Medicaid Services’ (CMS) Office of the Actuary (OACT)). National... Continue reading
Posted Mar 20, 2017 at Policy and Medicine
Image
The meaning of effectiveness of healthcare compliance programs has shifted in recent years. This article examines that shift and what it means for the role of the Compliance Officer including the need to evaluate and oversee a portfolio of risks.... Continue reading
Posted Mar 20, 2017 at Policy and Medicine
Image
Dr. Rafael Fonseca, a Chair of the Department of Medicine at the Mayo Clinic in Arizona and Distinguished Mayo Investigator, recently wrote an editorial in The Hill, a Washington, DC, based newspaper focused on politics in Congress. In the editorial,... Continue reading
Posted Mar 17, 2017 at Policy and Medicine
Image
Recently, as part of the course Legal Compliance Essentials for Drug, Device and Biotech Companies, Mitchell Hamline Law School, students were asked to write about what they saw as the important emerging issues for life sciences and what compliance professionals... Continue reading
Posted Mar 17, 2017 at Policy and Medicine
Image
In early October, the Office of Inspector General (OIG) released a report monitoring the progress made by the Centers for Medicare and Medicaid Services (CMS) on preparing for the implementation of the new payment system for clinical laboratory tests, which... Continue reading
Posted Mar 16, 2017 at Policy and Medicine
Image
In mid-January, the Medicare Payment Advisory Commission (MedPAC) met and discussed a revised approach to clinician payment for Medicare Part B drugs. Under the new approach, the average sale price plus 6 percent (ASP + 6) payment methodology would be... Continue reading
Posted Mar 15, 2017 at Policy and Medicine
Image
The Centers for Medicare and Medicaid Services (CMS) has released a new report highlighting the growth in rebates from drug manufacturers to pharmacy benefit managers (PBMs) and insurers. However, the report notes that these rebates don’t necessarily amount to savings... Continue reading
Posted Mar 14, 2017 at Policy and Medicine
Image
A dozen doctors, pharmacy owners, and marketing professionals have been accused of being involved in a sham medical study used to bilk up to $102 million from Tricare, the publicly funded federal health program for military and their family members.... Continue reading
Posted Mar 13, 2017 at Policy and Medicine
Image
Sanofi Pasteur Inc., has agreed to pay $61.5 million in a five-year long class action brought by doctors alleging that the drug company violated antitrust laws with contracts for its pediatric vaccines, according to an agreement filed in federal court... Continue reading
Posted Mar 10, 2017 at Policy and Medicine
Image
Less than two weeks into his presidency, Donald Trump met with several leaders of pharmaceutical companies. During his campaign, he vocally criticized the rise of drug prices and occasionally faulted the government’s inability to negotiate directly on drugs purchased through... Continue reading
Posted Mar 9, 2017 at Policy and Medicine
Image
John Holland, former senior executive of Tenet Healthcare Corporation, was recently indicted for his alleged role in a $400 million scheme to defraud. The indictment alleges that the scheme to defraud victimized not only the U.S. government, but also the... Continue reading
Posted Mar 8, 2017 at Policy and Medicine
Image
A rule released earlier this year by the Centers for Medicare & Medicaid Services (CMS) may lead to an increase in cases involving the regulation. The new CMS Medicare overpayments rule, released in February, requires providers to return excessive reimbursements... Continue reading
Posted Mar 7, 2017 at Policy and Medicine
Image
Last month, we wrote about the Connecticut APRN policy that is starting to come to fruition. As we noted, the dates of reporting were different than what applicable manufacturers (GPO's, Distributors, Drug and Device Manufacturers) were expecting. At the time... Continue reading
Posted Mar 7, 2017 at Policy and Medicine
Image
The American Society of Clinical Oncology (ASCO) has removed all restrictions on author relationships previously in the 2013 Policy for Relationships with Companies statement, and all eligible manuscripts and abstracts otherwise will be considered for peer review, regardless of any... Continue reading
Posted Mar 6, 2017 at Policy and Medicine
Image
As America continues to discuss the increase in the cost of prescription drugs, Johnson & Johnson (J&J) has announced that it plans to disclose average price increases of its prescription drugs. High and rising prices have also infuriated doctors, insurance... Continue reading
Posted Mar 3, 2017 at Policy and Medicine